GFH312
Phase 2Small molecule
GFH312 is one of 30 small molecule programs targeting Peripheral Artery Disease. It is currently in Phase 2.
1
Indications
3
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Peripheral Artery Disease
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Benicar
NovartisApproved
Kuvan
BioMarin PharmaceuticalApproved
Xarelto
WWim Janssens
Approved
Glucophage
EMD SeronoApproved
Zocor
OOrganon and Co
Approved
Brilinta
AstraZenecaPhase 3
Acetylsalicylic Acid
BayerApproved
Bayer Aspirin
BayerPhase 3
Colcrys
Alnylam PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GFH312. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details